+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Devic's Syndrome Treatment Market by Treatment Type, Distribution Channel, End User - Global Forecast to 2030- Product Image
Devic's Syndrome Treatment Market by Treatment Type, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Devic's Syndrome Treatment Market by Treatment Type, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977777
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Devic's Syndrome Treatment Market grew from USD 220.27 million in 2024 to USD 230.71 million in 2025. It is expected to continue growing at a CAGR of 4.70%, reaching USD 290.17 million by 2030.

Mapping the Shifting Landscape of Devic’s Syndrome Treatment

Devic’s syndrome, also known as neuromyelitis optica, has emerged as a focal point for both clinical research and therapeutic innovation. Over the past decade, our understanding of the disease’s underlying immunopathology has deepened substantially, driving the development of novel interventions and challenging long-held treatment paradigms. As patient advocacy groups raise awareness and diagnostic criteria become more refined, a growing cohort of individuals receives timely, accurate diagnoses, fueling demand for targeted therapies.

This executive summary captures the current state of Devic’s syndrome treatment, spotlighting critical market drivers, competitive dynamics, and evolving regulatory landscapes. By examining breakthrough biologics alongside established immunosuppressants and supportive care measures, this overview sets the stage for a nuanced exploration of how stakeholders-from pharmaceutical innovators to healthcare providers-can align strategies with emerging patient needs. The ensuing analysis balances clinical efficacy data with market intelligence, ensuring decision-makers have the clarity required to navigate this complex therapeutic arena.

Pivotal Shifts Redefining Treatment Paradigms

The past few years have witnessed transformative shifts in how Devic’s syndrome is managed, ushering in an era of personalized medicine. Monoclonal antibodies, once confined to a limited clinical scope, now sit at the forefront of treatment protocols, offering unprecedented specificity against pathogenic antibodies. Meanwhile, refinements in plasma exchange technology have enhanced safety profiles and reduced procedural burdens, making this intervention more accessible across diverse healthcare settings.

Concurrently, advancements in biomarker discovery are enabling earlier intervention and more precise monitoring of disease activity. Digital health platforms have also gained traction, streamlining patient monitoring and adherence tracking outside traditional hospital walls. As stakeholders integrate real-world evidence with clinical trial data, treatment paradigms are shifting from reactive management to proactive, data-driven care pathways. This intersection of technology, targeted biology, and patient-centric models is reshaping the competitive terrain and redefining the measures of therapeutic success.

Analyzing the 2025 US Tariff Influence on Treatment Costs

The introduction of enhanced tariff structures in 2025 has created a ripple effect throughout the Devic’s syndrome treatment supply chain. Import duties on key biologics and specialized medical devices have driven up acquisition costs for hospital systems and specialty clinics, compelling manufacturers to revisit pricing strategies. Higher fees on raw materials have similarly pressured the cost base for small-molecule immunosuppressants, prompting several generic producers to explore local manufacturing partnerships to mitigate tariff impacts.

While some regional distributors have passed increased import costs directly onto end users, others have absorbed portions of the tariffs to preserve market share, sparking negotiations around rebate programs and volume-based discounts. Parallel adjustments in reimbursement policies have emerged as payers reevaluate formulary placements in light of shifting cost structures. As stakeholders adapt to this new fiscal environment, transparency in pricing and collaborative value-based contracting have become critical levers for balancing patient access with sustainable profitability.

In-Depth Segmentation Reveals Patient-Centric Market Layers

A nuanced segmentation analysis reveals how varied treatment modalities and distribution pathways intersect with end-user demands. By treatment type, corticosteroids remain a mainstay in acute management, with intravenous formulations favored for rapid intervention and oral therapies supporting longer-term maintenance. Immunosuppressants such as azathioprine and mycophenolate mofetil provide cost-effective relapse prevention, while targeted monoclonal antibodies-specifically eculizumab and inebilizumab-address refractory cases with high specificity. Within procedural interventions, both automated and manual plasma exchange techniques continue to evolve, enhancing procedural consistency and patient comfort. Complementary supportive therapy options, encompassing pain management protocols and physiotherapy regimens, underscore the importance of holistic care in improving quality of life.

Distribution channels span hospital pharmacies that cater to acute inpatient demand, online pharmacies that offer convenience and broad geographic reach, and retail pharmacies that serve outpatient and home care markets. End-user segments include home healthcare providers, where telemonitoring and self-administration protocols are expanding; hospitals, which remain central to advanced infusion therapies; and specialty clinics that lead in adopting the latest immunomodulatory treatments. This layered segmentation underscores the need for tailored strategies that align product positioning, patient education, and service delivery with the unique requirements of each market segment.

Regional Variations Inform Strategic Market Deployment

Regional dynamics play a pivotal role in shaping treatment adoption and access. In the Americas, established healthcare infrastructures and reimbursement frameworks have facilitated rapid uptake of high-cost biologics, although payer negotiations and formulary adjustments continue to influence pricing negotiations. Providers are increasingly integrating telehealth solutions to extend specialist consultations into underserved areas.

Across Europe, the Middle East and Africa, diverse regulatory regimes and varying levels of healthcare expenditure create a mosaic of market opportunities. Western European nations often lead in adopting novel therapies, supported by centralized purchasing agreements, while emerging markets in the Middle East and Africa prioritize scalable interventions and cost-effective immunosuppressants. Manufacturers are customizing market access strategies to account for these regional disparities.

In the Asia-Pacific region, a burgeoning patient population and growing awareness of neuromyelitis optica present ample growth prospects. Government initiatives to expand universal health coverage and local manufacturing incentives are accelerating both generic and biologic availability. Partnerships with regional distributors and technology transfer agreements are proving instrumental in addressing local affordability challenges.

Market Leaders and Emerging Innovators Shaping the Space

The competitive landscape is anchored by established pharmaceutical giants and agile biotechs pursuing differentiated pipelines. AstraZeneca’s stewardship of eculizumab has solidified its leadership in complement inhibition, while Horizon Therapeutics’ inebilizumab continues to gain ground through targeted efficacy data. Large-scale generics manufacturers, including Teva and Sandoz, maintain strong positions in the immunosuppressants segment, leveraging cost advantages and broad distribution networks.

Emerging players are also reshaping the space through strategic alliances and M&A activity. Collaborations between biotech startups and contract research organizations accelerate early-stage development, while licensing agreements grant larger firms access to novel clinical assets. Parallel investments in patient support platforms and educational initiatives enhance brand positioning and foster long-term physician relationships. As R&D pipelines mature, patent expirations will introduce new biosimilars, intensifying competition and driving down unit costs, particularly in markets with robust regulatory pathways for interchangeability.

Strategic Playbook for Stakeholders to Capitalize on Opportunities

Industry stakeholders must adopt a multifaceted approach to capture value in this evolving market. Manufacturers should diversify portfolios by balancing high-margin biologics with lower-cost immunosuppressants, thereby hedging against pricing pressures and tariff fluctuations. Strengthening partnerships with home healthcare providers and specialty clinics will optimize patient access and support adherence through integrated care models. Each channel requires bespoke engagement strategies, from digital education tools for online pharmacies to in-person training at hospital centers.

Payers and providers can explore value-based reimbursement models that align payment with real-world outcomes, mitigating cost concerns while incentivizing the adoption of high-cost therapies. Investment in robust pharmacovigilance and outcomes data collection will bolster negotiations and support formulary placements. Concurrently, policymakers should consider targeted tariff exemptions for essential therapies to preserve access without undermining domestic manufacturing objectives. By championing collaborative stakeholder ecosystems, industry leaders can navigate regulatory complexity and deliver superior patient outcomes.

Comprehensive Research Framework Driving Robust Insights

This analysis is grounded in a rigorous research framework that blends qualitative and quantitative methodologies. Secondary research included an exhaustive review of peer-reviewed journals, regulatory filings, payer policy documents, and industry conference proceedings. Primary research comprised in-depth interviews with KOLs, clinicians, pharmacoeconomic experts, and supply-chain partners, yielding granular insights into emerging clinical practices and distribution challenges.

Quantitative data collection covered shipment volumes, price trend analyses, and reimbursement rates across key markets. Data triangulation techniques were applied to reconcile discrepancies and validate market estimates. A proprietary scoring model evaluated competitive positioning based on R&D activity, pipeline maturity, and commercial performance. The synthesis of these multiple data streams ensured a balanced perspective, minimizing bias and enhancing the reliability of strategic recommendations.

Synthesizing Insights for a Clear Strategic Roadmap

Through this strategic lens, the Devic’s syndrome treatment market emerges as a dynamic interplay of clinical innovation, regulatory nuance, and commercial strategy. Breakthrough biologics have redefined treatment efficacy, but sustainable growth will hinge on adaptive pricing, value-based contracting, and multi-channel engagement. Regional heterogeneity underscores the importance of localized market access initiatives, while segmentation analysis highlights patient-centric care pathways as a catalyst for differentiation.

As tariff landscapes and reimbursement policies continue to evolve, stakeholders must remain agile, leveraging real-world evidence and collaborative partnerships to address affordability and access. The convergence of digital health, biomarker-driven personalization, and integrated care platforms promises to elevate patient outcomes, yet success will depend on cohesive strategies that align R&D investment with market realities. Armed with the insights presented herein, decision-makers are well positioned to navigate complexity, mitigate risk, and capture emerging opportunities in the Devic’s syndrome treatment arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Corticosteroids
      • Intravenous
      • Oral
    • Immunosuppressants
      • Azathioprine
      • Mycophenolate Mofetil
    • Monoclonal Antibodies
      • Eculizumab
      • Inebilizumab
    • Plasma Exchange
      • Automated
      • Manual
    • Supportive Therapy
      • Pain Management
      • Physiotherapy
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Home Healthcare
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Viela Bio, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Devic's Syndrome Treatment Market, by Treatment Type
8.1. Introduction
8.2. Corticosteroids
8.2.1. Intravenous
8.2.2. Oral
8.3. Immunosuppressants
8.3.1. Azathioprine
8.3.2. Mycophenolate Mofetil
8.4. Monoclonal Antibodies
8.4.1. Eculizumab
8.4.2. Inebilizumab
8.5. Plasma Exchange
8.5.1. Automated
8.5.2. Manual
8.6. Supportive Therapy
8.6.1. Pain Management
8.6.2. Physiotherapy
9. Devic's Syndrome Treatment Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Devic's Syndrome Treatment Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Clinics
11. Americas Devic's Syndrome Treatment Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Devic's Syndrome Treatment Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Devic's Syndrome Treatment Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Alexion Pharmaceuticals, Inc.
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.3. Viela Bio, Inc.
14.3.4. Chugai Pharmaceutical Co., Ltd.
14.3.5. Teva Pharmaceutical Industries Ltd.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. DEVIC'S SYNDROME TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DEVIC'S SYNDROME TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DEVIC'S SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DEVIC'S SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DEVIC'S SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DEVIC'S SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY INEBILIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MANUAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 55. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 57. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 58. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 59. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CANADA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 106. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. GERMANY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 114. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FRANCE DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 128. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 130. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 131. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 132. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 138. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SPAIN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 170. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. DENMARK DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 184. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 185. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 186. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 187. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 188. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. QATAR DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 194. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FINLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 218. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. EGYPT DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. TURKEY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 242. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. NORWAY DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 248. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 249. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 250. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 251. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 252. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. POLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 273. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 274. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 275. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 276. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 277. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. CHINA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 280. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 281. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 282. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 283. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 284. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 285. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. INDIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 291. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 293. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. JAPAN DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY PLASMA EXCHANGE, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA DEVIC'S SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA DEV

Companies Mentioned

The companies profiled in this Devic's Syndrome Treatment market report include:
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Viela Bio, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 230.71 Million
Forecasted Market Value ( USD ) by 2030 $ 290.17 Million
Compound Annual Growth Rate4.7%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Neuromyelitis Optica - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025 - Product Image

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030 - Product Image

Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Chronic Fatigue Syndrome Treatment Market by Treatment Type, End User, Distribution Channel, Practitioner Type - Global Forecast to 2030 - Product Image

Chronic Fatigue Syndrome Treatment Market by Treatment Type, End User, Distribution Channel, Practitioner Type - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From

About the Market

Neuromyelitis Optica (NMO) is a rare autoimmune disorder of the central nervous system (CNS) that affects the optic nerves and spinal cord. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which can lead to permanent vision loss and paralysis. Treatment of NMO is focused on reducing inflammation and preventing further damage to the CNS. Drugs used to treat NMO include corticosteroids, immunosuppressants, and monoclonal antibodies. Corticosteroids are used to reduce inflammation and prevent further damage to the CNS. Immunosuppressants are used to reduce the activity of the immune system and prevent further attacks. Monoclonal antibodies are used to target specific molecules involved in the autoimmune response. The NMO drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of NMO and the development of new treatments. Companies in the NMO drug market include Biogen, Alexion Pharmaceuticals, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.